Pathological cardiac hypertrophy is a major predictor for the development of cardiac diseases. It is associated with chronic neurohumoral stimulation and with altered cardiac Ca 2+ signalling in cardiomyocytes. TRPC proteins form agonist-induced cation channels, but their functional role for Ca 2+ homeostasis in cardiomyocytes during fast cytosolic Ca 2+ cycling and neurohumoral stimulation leading to hypertrophy is unknown.
Aims
Pathological cardiac hypertrophy is a major predictor for the development of cardiac diseases. It is associated with chronic neurohumoral stimulation and with altered cardiac Ca 2+ signalling in cardiomyocytes. TRPC proteins form agonist-induced cation channels, but their functional role for Ca 2+ homeostasis in cardiomyocytes during fast cytosolic Ca 2+ cycling and neurohumoral stimulation leading to hypertrophy is unknown.
Methods and results
In a systematic analysis of multiple knockout mice using fluorescence imaging of electrically paced adult ventricular cardiomyocytes and Mn 2+ -quench microfluorimetry, we identified a background Ca 2+ entry (BGCE) pathway that critically depends on TRPC1/C4 proteins but not others such as TRPC3/C6. Reduction of BGCE in TRPC1/C4-deficient cardiomyocytes lowers diastolic and systolic Ca 2+ concentrations both, under basal conditions and under neurohumoral stimulation without affecting cardiac contractility measured in isolated hearts and in vivo. Neurohumoral-induced cardiac hypertrophy as well as the expression of foetal genes (ANP, BNP) and genes regulated by Ca 2+ -dependent signalling (RCAN1-4, myomaxin) was reduced in TRPC1/C4 knockout (DKO), but not in TRPC1-or TRPC4-single knockout mice. Pressure overload-induced hypertrophy and interstitial fibrosis were both ameliorated in TRPC1/C4-DKO mice, whereas they did not show alterations in other cardiovascular parameters contributing to systemic neurohumoralinduced hypertrophy such as renin secretion and blood pressure.
Conclusions
The constitutively active TRPC1/C4-dependent BGCE fine-tunes Ca 2+ cycling in beating adult cardiomyocytes.
TRPC1/C4-gene inactivation protects against development of maladaptive cardiac remodelling without altering cardiac or extracardiac functions contributing to this pathogenesis.
Introduction
Pathological cardiac hypertrophy is a major predictor for the development of cardiac diseases. 1 In cardiomyocytes, neurohumoral stimuli such as catecholamines or angiotensin II (AngII) activate G-protein-dependent signalling pathways that stimulate Ca 2+ dependent processes leading to myocyte growth and cardiac hypertrophy. 2 Beating cardiomyocytes display fast cytosolic Ca 2+ cycling originating from a spatiotemporally coordinated interplay of voltage-gated Ca 2+ channels, Na + -Ca 2+ exchangers, ryanodine receptors, and plasma membrane and SERCA pumps. 3 It is unclear to which extent cardiac remodelling processes associated with cardiac hypertrophy are caused solely by modulating channels and pumps involved in fast Ca 2+ cycling or whether alternative Ca 2+ entry pathways may fine-tune cardiac Ca 2+ homeostasis persistently and contribute to cardiac hypertrophy. 4 A longer lasting modulation of diastolic Ca 2+ levels has been suggested as a regulatory mechanism for the development of cardiac hypertrophy, which can result from alterations of sarcoplasmic reticulum (SR) Ca 2+ release and/ or by altered expression of proteins involved in plasma membrane Ca 2+ transport. 4 The complexity of Ca 2+ -dependent regulation of cardiac hypertrophy in vivo becomes evident as a large increase or reduction of voltage-gated L-type Ca 2+ currents both result in mild cardiac hypertrophy. 5, 6 TRPC proteins form ion channels that contribute to Ca 2+ entry directly or indirectly through activation of voltage-gated Ca 2+ channels. 7 The effects of over-expressing TRPC transgenes or dominant negative variants and knockdown of TRPC genes suggested that members of the TRPC subfamily may be involved in cardiac Ca 2+ signalling and hypertrophy development. 8 -12 However, their impact on the diastolic level and amplitude of fast cytosolic Ca 2+ cycling in beating adult cardiomyocytes and during neurohumoral stimulation triggering hypertrophy is unknown. Nevertheless, it was proposed that substances antagonizing TRPC channels may work as drugs to suppress cardiac hypertrophy. To develop such antagonists, it has to be considered, which specific members of the TRPC subfamily are essential constituents of channels involved in cardiac remodelling processes. Additionally, it is still unknown whether these proteins affect other cardiovascular functions and whether extracardiac TRPC channels alter the development of cardiac hypertrophy. Here, we identify TRPC1 and TRPC4 as constituents of a novel background Ca 2+ entry (BGCE) pathway in adult cardiomyocytes, which determines diastolic and systolic Ca 2+ concentrations in beating cells. TRPC1 and TRPC4 together are required for maladaptive cardiac remodelling without affecting cardiac contractility and rhythmicity or systemic blood pressure.
Methods
An expanded Materials and methods is available at Supplementary material online.
Animal experiments
All animal experiments were reviewed and approved in accordance with the ethic regulations and the animal welfare committees of the Universities of Saarland and Heidelberg. Isoproterenol (Iso, 30 mg/kg/day) and AngII (3 mg/kg/day) were infused via Alzet pumps over 7 and 14 days, respectively; pumps filled with saline (NaCl 0.9%) were used as control. Blood pressure and heart rate were measured with telemetric transmitters (PA-C10, Data Science International). Ivabradine was administered via chow pellets. Transverse aortic constriction (TAC, 5 weeks) was performed by tying a suture ligature against a 27-gauge needle and control mice underwent a sham operation. Plasma angiotensinogen and AngII concentrations were determined by Angiotensinogen (JP27413, IBL, Germany) and AngII (Uscn, Life Science Inc.) ELISA assays. Renin activity from the perfusate of isolated kidneys was determined from quantification of AngI by radioimmunoassay (Byk and DiaSorin). To measure cardiac function, a conductance catheter (SPR-835, Millar) inserted into the left ventricular from hearts mounted in a working heart apparatus (Hugo Sachs Elektronik-Harvard) was used. Cardiac dimensions and contractility were assessed by echocardiography under anaesthesia (1.5% Isoflurane) using a Vevo 770 system (Visualsonics). 
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RNA isolation and expression analysis
Total heart RNA was isolated with peqGOLD-RNAPure reagent (peqLab) and purified by extraction steps with diethyl ether. Quantity, purity, and integrity of the RNA samples were controlled by spectrophotometry (NanoQuant, Tecan) and microfluidic analysis (Bioanalyzer 2100, J.E. Camacho Londoño et al. 
Agilent Technologies
Histopathological analysis
Images were acquired with a digital colour camera (MRc5, Zeiss) and were analysed with the AxioVision software (Zeiss). To quantify the cross-sectional area .100 cells/mouse were analysed through the left ventricle free wall. Quantification of interstitial cardiac fibrosis was performed with the AutoMeasure module of AxioVision software 4.8.1 (Zeiss).
Data analysis
Analyses were made with Origin v8. Figure 1A and B) whereas the post-rest behaviour of global calcium transients ( Figure 1A ) and the current density of voltage-gated L-type Ca TRPC1/C4 in pathological cardiac remodelling channels (see Supplementary material online, Figure S1A ) were unaltered in TRPC1/C4-DKO. Sarcoplasmic reticulum-Ca 2+ content, estimated from the amplitude of caffeine-induced Ca 2+ transients, was reduced under resting and steady-state conditions; however, Ca 2+ extrusion, which is mainly mediated by NCX activity in mice 13 and can be correlated with the decay time constant of the caffeine-induced transients ( Figure 1C) , was unchanged in TRPC1/C4-DKO mice as was the decay of electrically evoked Ca 2+ transients, which correlates with SERCA activity (see Supplementary material online, Figure S1B ). Analysis of Ca 2+ sparks revealed that the amplitude and frequency of Ca 2+ , but not the decay time constant and spatial spread, were reduced in cells from TRPC1/C4-DKO ( Figure 1D ). Figure S1C ) or deletion of TRPC3/C6 proteins ( Figure 2B ). Importantly, we found a significantly larger Mn 2+ entry in WT cardiomyocytes after chronic neurohormonal stimulation with Iso or AngII but this increase was abrogated in TRPC1/ C4-DKO cells ( Figure 2C ). Next, we addressed the question whether and how the lack of TRPC1/C4 might modulate Iso-and AngII-evoked changes of Ca 2+ transients. In cardiomyocytes from WT and TRPC1/C4-DKO mice application of Iso resulted in an equal relative increase in the amplitude of Ca 2+ transients, whereas peak Fura2-ratios were substantially reduced in TRPC1/C4-DKO mice ( Figure 3A ; see Supplementary material online, Figure S2A ). Interestingly, both, peak Fura2-ratios and their relative increases during AngII-application, were significantly reduced ( Figure 3B ; see Supplementary material online, Figure S2B ). In cardiomyocytes from TRPC3/C6-DKO mice, Ca 2+ responses to Iso or AngII stimulation were not altered (Figure 3C and D; see Supplementary material online, Figure S2C and D).
TRPC1/C4-DKO are protected from development of maladaptive cardiac hypertrophy
To identify the contribution of BGCE and TRPCs (see Supplementary material online, Figure S3 ) to the development of cardiac hypertrophy, we analysed responses of TRPC1/C4-DKO mice to systemic infusion of Iso or AngII, or to increased afterload (TAC). In TRPC1/C4-DKO mice, cardiac hypertrophy was significantly reduced in all three conditions ( Figure 4A and B). TRPC1 and TRPC4 are thought to interact with TRPC5, 14 which appears to be upregulated in patients with cardiac failure. 15 We therefore analysed TRPC1/C4/5 triple KO mice and found no additional reduction in Iso-induced hypertrophy compared with TRPC1/C4-DKO mice (see Supplementary material online, Figure S4 ). However, mice lacking either TRPC1 or TRPC4 showed no reduced Iso-or AngII-induced hypertrophy responses (see Supplementary material online, Figure S5 ). Because cardiac-specific over-expression of TRPC6 and TRPC3 resulted in cardiac hypertrophy and failure, 11, 12 we tested whether both proteins have a causative role in these processes. We analysed TRPC3/C6-DKO mice to avoid compensatory effects of these TRPCs, 16 but cardiac hypertrophy and fibrosis
were not reduced ( Figure 4C ; see Supplementary material online, Figure S6 ). In adverse cardiac remodelling, myocardial hypertrophy is accompanied by reduction of cardiac function, interstitial fibrosis, and the activation of a foetal gene program. In TRPC1/C4-DKO mice, both the TAC-evoked reduction in ejection fraction (WT: 228.6%, DKO: 214.1%; Figure 5A and Table 1 ) and the interstitial fibrosis ( Figure 5B) were reduced by 50%. Accordingly, AngII-induced increases in col1a1, col3a1, and col4a1 ( Figure 5C ) and in foetal gene expression, i.e. Nppa and Nppb ( Figure 5D ), were diminished. To characterize Ca 2+ -dependent downstream signalling pathways involved in adverse cardiac remodelling, we quantified the expression RCAN1-4 as an endogenous calcineurin reporter 17 and myomaxin as a transcriptional target of MEF2a. 18 Expression of both was reduced in TRPC1/C4-DKO mice ( Figure 5E ).
Systemic pathways possibly contributing to the reduced cardiac hypertrophy in TRPC1/C4-DKO mice
Systemic administration of Iso or AngII activates signalling pathways in multiple organ systems that could influence the development of cardiac hypertrophy. However, Iso-induced renin release and its suppression by AngII were unaffected in TRPC1/C4-DKO ( Figure 6A ), as well as plasma AngII and angiotensinogen concentrations ( Figure 6B) . Likewise, Iso infusion resulted in a transient TRPC1/C4 in pathological cardiac remodelling increase in mean arterial blood pressure (MAP), but it was indistinguishable from pre-implantation levels at Day 7 in both genotypes, while hypertrophic responses were still reduced ( Figure 6C, inset) . In contrast, AngII infusion in WT mice resulted in an 45 mmHg increase in MAP (145.4 + 10.2 mmHg; n ¼ 5, P ¼ 0.0006), but hypertrophy development was smaller compared with Iso treatment (see Supplementary material online, Figure S7A ) supporting our notion that reduced hypertrophy in TRPC1/C4-DKO mice was not dependent on altered MAP responses. Intra-ventricular pressure measurements performed at the end of Iso treatment revealed no alterations in contractility in TRPC1/C4-DKO mice (see Supplementary material online, Table S1 ). Comparable results were acquired from working heart experiments using untreated mice except of a 12% increase in time constant of relaxation ( Table 2) . Nevertheless, parameters of the end-diastolic pressure-volume relationship were not altered in untreated TRPC1/C4-DKO mice and a detailed echocardiographic analysis revealed normal systolic and diastolic functions ( Table 1) .
Because elevations in the beating frequency can increase diastolic Ca 2+ concentrations and induce hypertrophy 19 and Iso-induced chronotropic responses were reduced in TRPC1/C4-DKO mice ( Figure 6D ), we evaluated whether this impaired response may contribute to the protection of hypertrophy development in TRPC1/ C4-DKO mice. We used Ivabradine to decrease heart rates before ( Figure 6E ) and during Iso infusion ( Figure 6E and F ) ; however, Ivabradine did not reduce Iso-induced hypertrophy ( Figure 6E and F ).
Discussion
Here, we identified a novel TRPC1/C4-dependent constitutively active BGCE pathway in cardiomyocytes that fine- 27 which mediates growth of cultured cardiomyocytes. 28 Our experiments demonstrate that development of cardiac hypertrophy is not reduced in TRPC1-or TRPC4-single KO mice. Seth et al. 10 showed a reduced hypertrophic response induced by pressure overload or AngII administration in TRPC1-KO mice; however, their induction protocols and genetic background of the TRPC1-KO mice were different from ours. We further addressed the question whether TRPCs in noncardiac tissues play a role in the development of cardiac hypertrophy. Both, TRPC1 and TRPC4 are expressed in the kidney, suggesting that they may regulate blood pressure and/or renin secretion; however, we ruled out both possibilities. Additionally, the reduced Iso-evoked chronotropic response following inactivation of TRPC1/TRPC4, which may be caused by the lack of their modulatory role on sinoatrial node pacemaking 29 is very unlikely to affect hypertrophy development since reduction of positive chronotropy using Ivabradine did not protect from development of cardiac hypertrophy as suggested by in vitro models. 19 Additionally, in TRPC1/C4-DKO basal cardiac contractility assessed by echocardiography and working heart showed no compromising differences.
In contrast, we demonstrate that TRPC1/TRPC4 inactivation protected against cardiac dysfunction evoked by chronically increased afterload. Analysis of downstream signalling pathways revealed that the up-regulation of RCAN1-4 and myomaxin expression in the heart is mitigated in the absence of TRPC1/C4 implicating that TRPC1/ C4-mediated BGCE contributed to the activation of the calcineurin-NFAT pathway. Myomaxin is a transcriptional target of MEF2a which acts as an integrator of multiple Ca 2+ -dependent signalling molecules including calcineurin and CaMKII 30 in the regulation of transcriptional activity. 31 Although the exact signalling cascade activated by BGCE needs to be explored, our results indicate that BGCE contributes to transcriptional reprogramming of the stressed myocardium including up-regulation of hypertrophyassociated foetal and collagen genes and development of interstitial fibrosis emphasizing its relevance for maladaptive cardiac remodelling processes.
In conclusion, TRPC1 and TRPC4 together form a novel BGCE which determines diastolic and systolic Ca 2+ as well as their modulation by neurohumoral stimulation in beating cardiomyocytes. It is essential for the development of cardiac hypertrophy and fibrosis in mice. Because the deletion of either TRPC1 or TRPC4 alone appears to be compensated by TRPC4 or TRPC1, respectively, genetic strategies or small molecules specifically targeting the TRPC1/ C4-containing Ca 2+ entry channel complexes in the heart might represent a promising approach to ameliorate the development of pathological cardiac remodelling in vivo without altering blood pressure or cardiac contractility.
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Supplementary Material is available at European Heart Journal online.
